Pubblicazioni

Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease

2020 - THE ONCOLOGIST

Ali, S.; Moreau, A.; Melchiorri, D.; Camarero, J.; Josephson, F.; Olimpier, O.; Bergh, J.; Karres, D.; Tzogani, K.; Gisselbrecht, C.; Pignatti, F.

National Italian Delphi panel consensus: Which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?

2020 - BMC CANCER

Lussana, F.; Minetto, P.; Ferrara, F.; Chiaretti, S.; Specchia, G.; Bassan, R.

Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group

2015 - HAEMATOLOGICA

D'AngiÃ², M; Valsecchi, Mg; Testi, Anna Maria; Conter, V; Nunes, Vittorio; Parasole, R; Colombini, A; Santoro, N; Varotto, S; Caniglia, M; Silvestri, D; Consarino, C; Levati, L; Magrin, E; Locatelli, F; Basso, G; Foa, Roberto; Biondi, A; Cazzaniga, G.